PIK3CA and neoplasm: Constitutive activation of PI3K pathway by PTEN mutation/loss or PIK3CA mutation could render tumor cells independent of RTKs for malignant transformation and maintenance, which leads to resistance to HER2-targeted therapies in BC and EGFR-targeted therapies in glioma [15–20].